Breast cancer
Conditions
Interventions
Gold Standard:DNA sequencing
Index test:A Multimodal Screening and Diagnostic Model for BRCA1/2 Gene Mutations Based on Breast Cancer Imaging Pathomics.
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years. 2.Histologically confirmed diagnosis of invasive breast cancer. 3.Completion of multigene germline mutation testing, including BRCA1/2 genes. 4.Availability of complete: personal medical history, clinicopathological data, family history of cancer. 5.Availability of pretreatment pathological slide images of primary lesions with hematoxylin and eosin (H&E) staining, obtained prior to pharmacotherapy or radiotherapy. 6.Availability of pretreatment contrast-enhanced breast MRI (magnetic resonance imaging) data.
Exclusion criteria
Exclusion criteria: 1.Failure to provide complete: personal medical history, family cancer history, clinicopathological data; 2.Breast cancer H&E-stained pathological slides meeting either of the following: obtained after neoadjuvant therapy, showing only ductal carcinoma in situ (DCIS); 3.Incomplete breast MRI imaging sequences, including but not limited to: non-contrast scans without contrast-enhanced sequences, missing key anatomical planes (e.g., axial/sagittal/coronal); 4.Incomplete BRCA1/2 gene testing: testing limited to hotspot mutations without full gene sequencing, lack of comprehensive variant analysis (e.g., large genomic rearrangements not assessed);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy;F1 score; | — |
Countries
China
Contacts
Public ContactWenming Cao
Zhejiang Cancer Hospital
Outcome results
None listed